CDXC Wutah pendapatan kuartal marang kuartal ChromaDex Corp.

Simbol resmi perusahaan chromadex.com (CDXC)

Rob Fried's strategic control and strong management drive the expansion of patented components for ChromaDex Corporation (CDXC). Line automation and AI-driven formulation control at plants reduce costs, while the quarterly revenue growth trajectory confirms business resilience, where the 37.90 mark indicates the yield level. Leading cellular senescence scientists, developing innovative longevity formulas in state-of-the-art laboratories, sustain this stability.

CDXC (ChromaDex Corp) riwayat Wutah pendapatan triwulanan saka 04.07.2022 nganti 19.03.2025

Rincian analitis lan laporan data perusahaan chromadex.com (CDXC)

- kuotasi saiki lan rata-rata prakiraan nilai:
- data saldo dhuwit lan arus kas:
Pambiji fundamental:ChromaDex Corp - CDXC
Produk sing diprodhuksi ChromaDex Corporation

ChromaDex Corporation (CDXC) leadership in the NAD+ segment and its Niagen patents drive the company's commercial success through demand for cellular regeneration. Quarterly sales dynamics measure the percentage change in revenue over three months, allowing investors to assess operational resilience and the risk of business overheating by analyzing the current level of quarterly sales growth.